[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353307-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-353307-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","the-central-role-of-il-6-in-the-differential-effects-of-glp-1-receptor-agonists-and-metformin-across-multiple-health-conditions","The central role of IL-6 in the differential effects of GLP-1 receptor agonists and metformin across multiple health conditions","","An earlier hypothesis links elevated TGF-b1 with IL-1b and IL-6 to neutrophilic asthma, cancer risk, and metabolic dysregulation. This article evaluates how IL-1b, IL-6, and TGF-b/Smad signaling help explain differences in therapeutic efficacy and safety between GLP-1 receptor agonists (GLP-1 RAs) and metformin across multiple conditions. Integrating published evidence, stronger IL-6 suppression may underlie superior glucose control, insulin sensitivity in PCOS, cardiovascular risk reduction, and fewer osteoarthritis-related perioperative infections, while weight loss appears IL-6 independent. Systemic IL-6 suppression may also increase allergic adverse effects, whereas shared gastrointestinal pathway interference likely drives GI events. Metformin may better address general asthma and osteoarthritis pain, and similar cancer risk reduction may reflect limited cancer effects of IL-6 pathway inhibitors.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-central-role-of-il-6-in-the-differential-effects-of-glp-1-receptor-agonists-and-metformin-across-multiple-health-conditions/353307/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-central-role-of-il-6-in-the-differential-effects-of-glp-1-receptor-agonists-and-metformin-across-multiple-health-conditions/353307.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-09-24","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":26},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What earlier hypothesis does the article build on?","Question",{"text":62,"@type":63},"It builds on an earlier publication proposing that elevated TGF-b1 together with IL-1b and IL-6 drives neutrophilic asthma, increases cancer risk, and is linked to metabolic dysregulation.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How does IL-6 suppression relate to the efficacy of GLP-1 receptor agonists versus metformin?",{"text":67,"@type":63},"Stronger suppression of circulating IL-6 is suggested to contribute to greater efficacy of GLP-1 RAs for lowering blood glucose and improving insulin sensitivity, including in PCOS, and for reducing cardiovascular risk and osteoarthritis-related perioperative infections.",{"name":69,"@type":60,"acceptedAnswer":70},"Why might GLP-1 receptor agonists and metformin differ in adverse effect profiles?",{"text":71,"@type":63},"The article proposes that systemic IL-6 suppression may explain higher frequencies of allergic adverse effects with GLP-1 RAs, while local interference with IL-6 signaling in the gastrointestinal tract—shared by both agents—may account for common gastrointestinal adverse events.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},353307,1790211430,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":26,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Hypothesis and Theory PUBLISHED 21 July 2026  \nDOI 10.3389/fimmu.2026.1864104  \nOPEN ACCESS  \nEDITED BY  \nLi-Tung Huang,  \nKaohsiung Chang Gung Memorial Hospital, Taiwan  \nREVIEWED BY  \nHua Tang,  \nShandong First Medical University, China Alessandra Tomasello,  \nUniversity of Palermo, Italy  \n*CORRESPONDENCE  \nZeev Elkoshi  \n [zeev.elkoshi@gmail.com](zeev.elkoshi@gmail.com)  \nRECEIVED 24 April 2026  \nREVISED 18 June 2026  \nACCEPTED 22 June 2026  \nPUBLISHED 21 July 2026  \nCITATION  \nElkoshi Z (2026) The central role of IL-6 in the differential effects of GLP-1 receptor agonists and metformin across multiple health conditions.  \nFront. Immunol. 17:1864104 .  \ndoi: 10.3389/fimmu.2026.1864104  \nCOPYRIGHT  \n© 2026 Elkoshi. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe central role of IL-6 in the differential effects of GLP-1 receptor agonists and metformin across multiple health conditions  \nZeev Elkoshi*  \nRetired, Kfar Saba, Israel  \nAn earlier publication suggested that elevated TGF-b1 together with IL-1b and IL- 6 drives neutrophilic asthma, increases cancer risk, and is associated with metabolic dysregulation. This article examines how these cytokines shape the therapeutic efficacy and safety profiles of GLP-1 RAs compared with metformin. Integrating published data, stronger suppression of circulating IL-6 likely contributes to the superior efficacy of GLP-1 RAs in lowering blood glucose, improving insulin sensitivity in patients with polycystic ovary syndrome (PCOS), reducing cardiovascular risk, and reducing osteoarthritis-related perioperative infections, but not to their superior weight-loss effects. Superior weight loss, which is IL-6 independent, further enhances the efficacy of GLP-1 RAs in improving metabolic dysfunction–associated steatohepatitis (MASH), PCOS, and survival in cancer patients. Systemic IL-6 suppression may also explain the higher frequency of allergic adverse effects with GLP-1 RAs, whereas local interference with IL-6 signaling in the gastrointestinal tract, shared by both agents, likely accounts for frequent gastrointestinal adverse events reported with both. Although metformin may be more effective in improving asthma outcomes in the general asthma population, GLP-1 RAs are likely to be more effective inneutrophilic asthma. Metformin also reduces osteoarthritis-related joint pain, consistent with the limited efficacy of IL-6R inhibition in reducing this pain. Finally, the lack of effect of IL-6 pathway inhibitors on cancer incidence may explain the similar efficacy of GLP-1 RAs and metformin in reducing the risk of most cancers.  \nKEYWORDS  \ncancer, cardiovascular disease, GLP-1 receptor agonists, metabolic dysfunction– associated steatohepatitis, metabolic dysregulation, metformin, osteoarthritis, polycystic ovary syndrome  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nElkoshi 10.3389/fimmu.2026.1864104  \nGRAPHICAL ABSTRACT  \nIntroduction  \nGlucagon-like peptide-1 receptor agonists (GLP-1RAs), initially introduced for type 2 diabetes (T2D), have increasingly become central to medical obesity treatment. In clinical trials, these agents frequently achieve 15–20% reductions in body weight, marking a substantial therapeutic impact. The regulatory authorization of liraglutide, semaglutide, and tirzepatide for long-term weight management has further broadened their clinical application (1) . Multiple large cardiovascular outcomes trials have shown that GLP-1 RAs lower the incidence of major adverse cardiovascular events (MACE) in patients with T2D who are at elevated cardiovascular ","cbCaidcnN8hltTch","https://ap.wps.com/l/cbCaidcnN8hltTch","pdf",2830158,27,"English","# Introduction\n## GLP-1 RAs downregulate IL-1b, IL-6, and the TGF-b/Smad signaling pathway in T2D patients","[{\"question\":\"What earlier hypothesis does the article build on?\",\"answer\":\"It builds on an earlier publication proposing that elevated TGF-b1 together with IL-1b and IL-6 drives neutrophilic asthma, increases cancer risk, and is linked to metabolic dysregulation.\"},{\"question\":\"How does IL-6 suppression relate to the efficacy of GLP-1 receptor agonists versus metformin?\",\"answer\":\"Stronger suppression of circulating IL-6 is suggested to contribute to greater efficacy of GLP-1 RAs for lowering blood glucose and improving insulin sensitivity, including in PCOS, and for reducing cardiovascular risk and osteoarthritis-related perioperative infections.\"},{\"question\":\"Why might GLP-1 receptor agonists and metformin differ in adverse effect profiles?\",\"answer\":\"The article proposes that systemic IL-6 suppression may explain higher frequencies of allergic adverse effects with GLP-1 RAs, while local interference with IL-6 signaling in the gastrointestinal tract—shared by both agents—may account for common gastrointestinal adverse events.\"}]","The central role of IL-6 in the differential effects of GLP-1 receptor agonists and metformin across multiple health conditions | PDF",1790104627,68]